. . . EXHIBIT 12.1 OSI PHARMACEUTICALS, INC. RATIO OF EARNING TO FIXED CHARGES SIX MONTHS SIX MONTHS ENDED ENDED MARCH 31, MARCH 31, 2004 2003 2003 2002 2001 2000 1999 ------------ ------------ ------------ ------------ ------------ ------------ ------------ Net loss (89,837,010) (57,269,035) (181,357,335) (218,479,106) (23,755,434) (16,347,569) (9,798,437) Equity losses -- -- 243,455 347,820 200,000 Cumulative effect of accounting change -- -- 2,625,000 ------------ ------------ ------------ ------------ ------------ ------------ ------------ Net loss before cumm effect and equity in investee (89,837,010) (57,269,035) (181,357,335) (218,479,106) (20,886,979) (15,999,749) (9,598,437) Add: Fixed charges 7,545,182 4,792,511 10,015,667 7,943,667 745,678 688,935 535,370 ------------ ------------ ------------ ------------ ------------ ------------ ------------ Net loss as adjusted (82,291,827) (52,476,524) (171,341,668) (210,535,439) (20,141,301) (15,310,814) (9,063,067) Fixed Charges: Interest (gross), including amortization of issuance costs 6,175,869 3,617,460 7,549,000 5,877,000 50,011 32,268 24,370 Estimated interest portion of rent 1,369,313 1,175,051 2,466,667 2,066,667 695,667 656,667 511,000 ------------ ------------ ------------ ------------ ------------ ------------ ------------ Fixed charges 7,545,182 4,792,511 10,015,667 7,943,667 745,678 688,935 535,370 ------------ ------------ ------------ ------------ ------------ ------------ ------------ Deficiency of earnings available to cover fixed charges (89,837,010) (57,269,035) (181,357,335) (218,479,106) (20,886,979) (15,999,749) (9,598,437) ============ ============ ============ ============ ============ ============ ============